ARS Pharmaceuticals, Inc Cash Flow
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
2023
2022
2021
2020
2019
-59M
-54M
0M
9M
-10M
-7M
-113M
0M
7M
0M
-0 %
0M
0M
-87M
71M
-140M
211M
-59M
-40M
-35M
0M
6M
1M
-13M
63M
0M
191M
0M
0 %
1M
-9M
199M
211M
150M
60M
-40M
-18M
-20M
0M
3M
0M
0M
0M
0M
53M
0M
-0 %
0M
-2M
0M
60M
36M
25M
-18M
9M
-1M
0M
4M
0M
6M
0M
1M
5M
0M
-0 %
0M
5M
-403M
25M
14M
10M
8M
-19M
-24M
2M
0M
0M
3M
0M
0M
9M
0M
-0 %
0M
0M
0M
10M
-10M
20M
-19M
Concept
Operating Cash Flow
Net Income
Depreciation & Amortization
Stock based compensation
Other non cash items
Change in working capital
Investing Cash Flow
Capital Expenditures
Financing Cash Flow
Dividends Paid
Payout Ratio
Share Issuance / Repurchase
Debt Issued / Paid
Other Investing Activities
End Cash Position
Changes in Cash
Beginning Cash Position
Free Cash Flow
4Q2023
3Q2023
2Q2023
1Q2023
4Q2022
3Q2022
2Q2022
1Q2022
4Q2021
3Q2021
2Q2021
1Q2021
-17M
-7M
0M
2M
9M
-11M
26M
0M
2M
0M
-0 %
0M
0M
26M
71M
10M
61M
-17M
-13M
-15M
0M
3M
-2M
1M
-47M
0M
1M
0M
-0 %
0M
0M
-47M
61M
-58M
119M
-13M
-17M
-17M
0M
2M
-2M
0M
45M
0M
3M
0M
-0 %
3M
0M
45M
119M
31M
88M
-17M
-12M
-15M
0M
2M
-2M
2M
-111M
0M
1M
0M
-0 %
1M
0M
-112M
88M
-123M
211M
-13M
-20M
-14M
0M
5M
1M
-12M
63M
0M
194M
0M
-0 %
-1M
-9M
200M
211M
173M
37M
-21M
-6M
-7M
0M
0M
0M
0M
0M
0M
-2M
0M
-0 %
1M
-1M
-2M
37M
-7M
45M
-6M
-7M
-6M
0M
0M
0M
-1M
0M
0M
-1M
0M
-0 %
0M
-1M
0M
45M
-8M
52M
-7M
-7M
-7M
0M
0M
0M
0M
0M
0M
-1M
0M
-0 %
0M
-1M
0M
52M
-8M
60M
-7M
-5M
-5M
0M
0M
0M
0M
0M
0M
27M
0M
-0 %
0M
-1M
0M
60M
22M
0M
0M
-5M
-5M
0M
0M
0M
0M
0M
0M
27M
0M
0 %
0M
-1M
0M
0M
22M
0M
0M
-4M
-5M
0M
0M
0M
0M
0M
0M
-1M
0M
0 %
0M
-1M
0M
0M
-4M
0M
0M
-4M
-5M
0M
0M
0M
0M
0M
0M
-1M
0M
0 %
0M
-1M
0M
0M
-4M
0M
0M